Skip to main content

Table 7 Mean Changes in SF-12 PCS and MCS Scores by Responder Status

From: Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia

 

Responders

Non-responders

Core Study BL

Extension Study BL

Extension Study EP

Core Study BL

Extension Study BL

Extension Study EP

 

N

31a

31b

25c

112a

112b

72c

PCS score

Mean Score (SD)

46.4 (11.4)

47.4 (10.7)

48.9 (9.9)

46.6 (10.4)

46.0 (9.9)

48.4 (9.3)

Change from Core BL (SD)

--

0.6 (9.6)

2.7 (6.7)

--

−0.5 (8.0)

2.5 (8.3)

p-value (between group)

--

0.239*

0.643**

--

--

--

MCS score

Mean Score (SD)

38.9 (8.6)

49.6 (11.5)

48.5 (9.0)

42.6 (11.6)

45.6 (11.0)

46.9 (9.8)

Change from Core BL (SD)

--

11.3 (10.1)

10.0 (10.1)

--

3.0 (11.3)

5.0 (10.1)

p-value (between group)

--

0.001*

0.280**

--

--

--

  1. Note: Extension study BL = 6-week follow-up; extension study BL = end of additional 24 weeks of treatment
  2. Abbreviations: BL baseline, EP endpoint, NE Not estimable, MCS Mental Component Summary, PCS Physical Component Summary, SD standard deviation, SF-12 Short Form 12
  3. aNumber of patients with SF-12 PCS/MCS scores at core study baseline
  4. bNumber of patients with SF-12 PCS/MCS scores at both core study baseline and extension study baseline
  5. cNumber of patients with SF-12 PCS/MCS scores at both core study baseline and extension study endpoint
  6. *P-value comparing mean changes in SF-12 PCS/MCS scores from extension study baseline to core study baseline between responders and non-responders
  7. **P-value comparing mean changes in SF-12 PCS/MCS scores from extension study endpoint to core study baseline between responders and non-responders